Test ID: CDAU5
Drug Abuse Survey with Confirmation, Panel 5, Urine
NY State Approved 
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Useful For Suggests clinical disorders or settings where the test may be helpful
Detecting drug abuse involving amphetamines, cocaine, marijuana, opiates, and phencyclidine
This test is intended to be used in a setting where the test results can be used definitively to make a diagnosis.
Some drug treatment programs do not require confirmatory testing of screen-positive specimens. In those settings, IDOAU/8248 Drug Abuse Survey, Urine is a less costly option.
Reflex Tests Lists test(s) that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial test(s)
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| AMPHU | Amphetamines, U | Yes | No |
| COKEU | Cocaine Confirmation, U | Yes | No |
| OPATU | Opiates, U | Yes | No |
| PCPU | Phencyclidine Confirmation, U | Yes | No |
| THCU | Tetrahydrocannabinol Conf, U | Yes | No |
Additional Tests Lists test(s) that are always performed, at an additional charge, with the initial test(s)
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| ADULT | Adulterants Survey, U | No | Yes |
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
Testing begins with immunoassay screen. Positives are confirmed and quantitated by gas chromatography-mass spectrometry at an additional charge.
An evaluation to detect the presence of adulterants will be performed and reported at no additional charge.
See Adulterant Survey Algorithm in Special Instructions.
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Method Name A short description of the method used to perform the test
CDAU5/80373: Screened by Immunoassay
ADULT/29345: Spectrophotometry (SP)
AMPHU/8257, COKEU/9286, OPATU/8473, PCPU/80371, THCU/8898: Gas Chromatography-Mass Spectrometry (GC-MS)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Aliases Lists additional common names for a test, as an aid in searching
Angel Dust (Phencyclidine)
Benzoylecgonine (Cocaine Metabolite)
Cannabinoids (Tetrahydrocannabinol)
Cocaine
Codeine
Coke (Cocaine)
Crack (Cocaine)
Desoxyn (Methamphetamines)
Dilaudid (Hydromorphone)
Drugs of Abuse
Ecstasy
Heroin
Hycodan (Hydrocodone)
Hydrocodone (Hycodan, Vicodin)
Hydromorphone (Dilaudid, Vicodin)
Killer Weed (Phencyclidine)
Lortab (Hydromorphone)
Marijuana (Tetrahydrocannabinol)
MDA (Methylenedioxyamphetamine) Metabolite for Methylenedioxyethylamphetamine (MDEA) and Methylenedioxymethamphetamine (MDMA)
MDMA (Methylenedioxymethamphetamine)
Methamphetamines (Desoxyn)
Methylenedioxyamphetamine (MDA) Metabolite for Methylenedioxyethylamphetamine (MDEA) and Methylenedioxymethamphetamine (MDMA)
Methylenedioxymethamphetamine (MDMA)
Morphine
Opiates
Oxycodone (Oxycontin, Percodan)
Oxycontin (Oxycodone)
PCP (Phencyclidine)
Percodan (Oxycodone)
Phencyclidine (PCP)
Rocket Fuel (Phencyclidine)
Speed (Amphetamines)
TCP (Phencyclidine)
Tetrahydrocannabinol (THC)
THC (Tetrahydrocannabinol)
Toxicology Screen, Drugs
Vicodin (Hydrocodone)
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Collection Container/Tube: Plastic urine container
Submission Container/Tube: Plastic, 60-mL urine bottle
Specimen Volume: 30 mL
Collection Instructions:
1. Collect a random urine specimen.
2. Submit 30 mL in 1 plastic bottle.
3. No preservative.
Additional Information:
1. No specimen substitutions.
2. No STATS are accepted for this procedure.
3. For situations where chain-of-custody is required, a Chain-of-Custody Kit (Supply T282) is available. For chain-of-custody information, see COCH/9426 Chain-of-Custody Processing.
4. Additional drug panels and specific requests are available. Call Mayo Medical Laboratories at 800-533-1710 or 507-266-5700.
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Reject Due To Identifies specimen types and conditions that may cause the specimen to be rejected
| Hemolysis | NA |
| Lipemia | NA |
| Icterus | NA |
| Other | NA |
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
| Specimen Type | Temperature | Time |
|---|---|---|
| Urine | Refrigerated (preferred) | 14 days |
| Frozen | 14 days | |
| Ambient | 72 hours |
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
This assay was designed to screen for and confirm by gas chromatography-mass spectrometry (GC-MS) the following drugs:
-Amphetamines
-Cocaine
-Opiates
-Phencyclidine
-Tetrahydrocannabinol
This assay represents the coupling of IDOAU/8248 Drug Abuse Survey, Urine with an automatic confirmation of all positive results by the definitive assay available and described elsewhere (eg, AMPHU/8257 Amphetamines, Urine). All positive screening results are confirmed by GC-MS or GC-FID, and quantitated, before a positive result is reported.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Negative
Screening cutoff concentrations
Amphetamines: 500 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Opiates: 300 ng/mL
Phencyclidine: 25 ng/mL
Tetrahydrocannabinol carboxylic acid: 20 ng/mL
This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.
Interpretation Provides information to assist in interpretation of the test results
A positive result indicates that the patient has used the drugs detected in the recent past. See individual tests (eg, AMPHU/8257 Amphetamines, Urine) for more information.
For information about drug testing, including estimated detection times, see Drugs of Abuse Testing at http://www.mayomedicallaboratories.com/articles/drug-book/index.html
Creatinine and specific gravity are measured as indicators of specimen dilution.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Not intended for use in employment-related testing.
The test does not screen for drug classes other than those listed above. More comprehensive screening is available using DSS/8421 Drug Screen, Prescription/OTC, Plasma or PDSU/88760 Drug Screen, Prescription/OTC, Urine.
For situations where chain-of-custody is required, a Chain-of-Custody Kit (Supply T282) is available. See COCH/9426 Chain-of-Custody-Processing.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Physicians Desk Reference (PDR). 60th edition. Montvale, NJ, Medical Economics Company, 2006
2. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th edition. Edited by LL Bruntman. New York, McGraw-Hill Book Company, 2006
3. Langman LJ, Bechtel L, Holstege CP: Chapter 35. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Edited by CA Burtis, ER Ashwood, DE Bruns. WB Saunders Company, 2011, pp 1109-1188
Method Description Describes how the test is performed and provides a method-specific reference
Drug classes are screened by an immunoassay technique. All positive screening results are confirmed by gas chromatography-mass spectrometry.(Armbruster DA, Schwarzhoff RH, Hubster EC, Liserio MK: Enzyme immunoassay, kinetic microparticle immunoassay, radioimmunoassay, and fluorescence polarization immunoassay compared for drugs-of-abuse screening. Clin Chem 1993;39:2137-2146; Ellis GM Jr, Mann MA, Judson BA, et al: Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther 1985;38:572-578)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Sunday
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
80104-Drug screen, qualitative, each procedure
G0431-Drug screen, qualitative, each specimen-government payers (if appropriate)
80299-Tetrahydrocannabinol carboxylic acid (if appropriate)
82145 x 2-Amphetamines (if appropriate)
82520-Cocaine (if appropriate)
83925-Opiates (if appropriate)
83992-Phencyclidine (if appropriate)
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
| Result ID | Reporting Name | LOINC Code |
|---|---|---|
| 2573 | Amphetamines | 20410-7 |
| 21652 | Cocaine | 20519-5 |
| 2577 | Opiates | 17384-9 |
| 2578 | Phencyclidine | 16254-5 |
| 2664 | Tetrahydrocannabinol | 3530-3 |
| 20672 | Chain of Custody | In Process |
External
link
PDF
document
Excel
document
Word
document